Core Viewpoint - Agomab (AGMB) has priced 12.5 million shares at $16.00, which is within the target range of $15.00 to $17.00, indicating strong market interest in the offering [1]. Company Overview - Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies specifically for immunology and inflammatory diseases [1]. - The company's initial focus is on chronic fibrotic indications that have a high unmet medical need, highlighting its commitment to addressing significant health challenges [1]. Offering Details - The share offering consists of 12.5 million shares priced at $16.00 each, which is positioned within the anticipated range [1]. - JPMorgan, Morgan Stanley, Leerink, and Kempen are serving as joint book-running managers for this offering, indicating a strong backing from reputable financial institutions [1].
Agomab indicated to open at $15.50, IPO priced at $16